> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Preserve Access to Compounded Hormones: APC
- URL: https://www.fdaweb.com/preserve-access-to-compounded-hormones-apc/
- Published: 2022-09-13T12:00:00.000Z
- Updated: 2026-09-14T17:59:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152718

The Alliance for Pharmacy Compounding (APC) has submitted a letter to FDA signed by about 2,000 prescribers of compounded hormones asking that the agency assure continued patient access to compounded hormone therapy. The [letter](https://a4pc.org/2022-08/1957-prescribers-tell-fda-preserve-access-to-compounded-hormones/?ref=fdaweb.com) is an effort to counter what APC says is a “flawed 2020 report FDA commissioned from the National Academies of Sciences, Engineering, and Medicine, and what the repercussions would be should FDA use that report as the basis for restricting access to compounded hormones.”

The prescribers say that access to compounded medications provides the ability for them to uniquely tailor and personalize medications to meet the needs of individual patients for whom, in the prescriber’s judgment, commercially available drugs are not suited. “By implementing across-the-board restrictions on compounded hormones,” APC says, it “would interfere with the practice of medicine and prevent \[the prescribers\] from treating their patients.”

The letter calls for expanded education on the use of bioidentical hormones for all healthcare practitioners involved in caring for patients, as well as the creation of a reasonable, consistent framework for adverse event reporting for compounded medications.